Lawmakers turned their sharp scrutiny of the 340B program on drugmakers Tuesday, questioning why states and providers don’t know the ceiling prices

Officials from two federal watchdogs told a Senate committee Tuesday that a drug discount program for hospitals needs additional transparency and oversight